Biotrial is proud to be a part of the PRIME Horizon2020 project, a collaborative effort between leaders in the neuroscience and endocrinology fields to investigate the link between insulin-related diseases and neuropsychiatric disorders, with a specific focus on the association between insulin resistance-related somatic conditions (such as obesity, type 2 diabetes, and cardiovascular diseases) and cognitive function.
Biotrial is proud to be a part of the PRIME Horizon2020. Together with other leaders in the Neuroscience and Endocrinology field, we are investigating the link between insulin-related diseases (such as obesity & type 2 diabetes), cardiovascular diseases, and neuropsychiatric disorders.
This review paper describes associations between insulin resistance-related somatic conditions (including obesity, type 2 diabetes and cardiovascular diseases) and cognition. It provides a solid rationale for further investigations with the goal of potentially identifying new therapeutic targets.
Insulin resistance, which occurs when the body’s cells become less responsive to insulin’s signals, is a common feature of obesity, type 2 diabetes, and cardiovascular diseases. High levels of glucose in the blood caused by insulin resistance can damage blood vessels and organs, including the brain. Research has shown that insulin resistance-related somatic conditions are associated with cognitive impairment and an increased risk of developing neuropsychiatric disorders such as depression, anxiety, and dementia. For example, individuals with type 2 diabetes are twice as likely to develop dementia compared to those without the condition.
The mechanisms underlying these associations are complex and not yet fully understood. However, researchers have proposed several theories, such as inflammation in the brain due to insulin resistance, and interference with the production and function of neurotransmitters.
The PRIME Horizon2020 project, which includes Biotrial as a key contributor, seeks to understand these mechanisms in greater detail and identify new therapeutic targets. Through their contributions to this important effort, Biotrial is committed to advancing the field of neuroscience and supporting the development of new treatments for neuropsychiatric disorders.